How can we speed up TB clinical trials efficiently? Our latest work led by global TB experts, under UNITE4TB defines the ideal biomarker assays to reliably track treatment response, therefore helping trials be faster, smarter and more effective. 👉 Read at: https://bit.ly/4iVmPAu

✨ With 2025 coming to an end, we at the AMR Accelerator are taking a moment to thank all our projects, partners, researchers and supporters. Wishing everyone of you a warm holiday season and see you again in 2026, where our story continues....

In our latest study under RespiriTB, researchers developed a fast “screening factory” to test hundreds of compounds against a key TB enzyme, mycothione reductase, which is crucial bacterial survival mechanism. 👉 𝗥𝗲𝗮𝗱 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/4orDHl4

Hear from Pedro Quintela in an interview about his work in GNA NOW advancing 𝘪𝘯 𝘷𝘪𝘷𝘰 proof-of-concept models for AMR research. He shares insights into: 🦠 Broader pathogen coverage 🤝 Interdisciplinary collaboration 💡 Championing the promise of each experiment https://bit.ly/49Hdtr1

In this latest study under @era4tb.bsky.social, researchers adopted physiologically‑based pharmacokinetic (PBPK) modelling and used a detailed computational model to project what those concentrations likely are in human lungs (both healthy and TB-infected). 👉 Read at: https://bit.ly/3KA2RQx

Webinar recording is now live! Previous month, a joint effort from COMBINE, ERA4TB AND GNA NOW (Lygature) under AMR Accelerator resulted in an exciting webinar on hollow fiber assays in antimicrobial drug development. Check out the key takeaways & watch the recording here https://bit.ly/4psEqDU

Our latest review under PrIMAVeRa maps out the evidence on bloodstream infections caused by six high-priority resistant pathogens. Finding? Lots of data on resistance percentage Little data on how many infections actually occur 👉 Read complete paper at: https://bit.ly/4rpZ1Kx

🚨 The AMR Accelerator needs your help! Our Machine Learning group seeks datasets to build a Gram-negative permeability prediction model. 𝗜𝗳 𝘆𝗼𝘂 𝗵𝗮𝘃𝗲 𝘀𝘂𝗶𝘁𝗮𝗯𝗹𝗲 𝗱𝗮𝘁𝗮𝘀𝗲𝘁𝘀, 𝗽𝗹𝗲𝗮𝘀𝗲 𝘃𝗶𝘀𝗶𝘁: https://bit.ly/4piUvMw Fill out a form and we will contact you!

We are excited to share the latest work under RespiriTB, published in Nature Communications! The study explores how targeting the M. tuberculosis cytochrome bc1 complex could unlock new treatment options for both DS-TB & MDR-TB. 👉 https://go.nature.com/48cWgEV

Hear from Marie Attwood (@reepkpd333.bsky.social) in an exclusive interview about her work in using 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 models in AMR research as a GNA NOW PK/PD expert. She offers insights into: 🔬 Decade of progression 🧫 Hollow-fibre modelling 🦠 AI-driven discovery 🔗 https://bit.ly/4plTnqW

Is this research unit ready to safely run a first-in-human trial? ERA4TB researchers designed a "feasibility form" that sets minimal criteria a Clinical Trial Unit must meet, jointly agreed by academia and industry, to follow key standards. 👉 Read complete paper at: https://bit.ly/486LwGK

As we approach the end of the year, the AMR Accelerator is only gaining momentum. With the #WAAW2025 underway, this month’s newsletter is a gentle nudge to our community, offering a clear snapshot of what has been happening across our projects and what is coming next. 👉 https://bit.ly/4o2iQEQ

📢 Thanks to the efforts of projects funded by IMI and @globalhealthedctp3.bsky.social, we're a step closer to getting a new weapon in the fight against #tuberculosis 💊 Get the full story & meet the people behind this work at our webinar on 9 Dec 👉 link.europa.eu/WbjvxK @amr-accelerator.bsky.social

#WAAW 2025 calls on all of us to act, because #AMR is no longer tomorrow’s problem. This week, #AMR Accelerator highlights researchers and leaders turning ideas into impact, protecting today and securing our future. 👉 Read the full feature here: https://bit.ly/3K7ECcb ‎

Our latest Primavera study shows Klebsiella pneumoniae, E. coli and MRSA cause the most preventable harm in surgical, cancer & transplant patients. The impact? Vaccines or mAbs could cut infections, hospital stays and antibiotic use. 👉 Read the full paper here: https://bit.ly/3JStwYn

𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗜𝘀 𝗡𝗼𝘄 𝗢𝗽𝗲𝗻!! Reserve your spot today for the upcoming COMBINE-GNA NOW and webinar on i𝘯 𝘷𝘪𝘵𝘳𝘰 standardisation in antimicrobial drug development. Register now to secure your spot: https://bit.ly/4nQvPsR

Innovative science alone will not end TB, it is just the start. True impact needs trials, policies and real-world action. UNITE4TB interviewed stakeholders to understand challenges & opportunities in turning TB innovation into real impact. Read complete paper at: https://bit.ly/4pe6GtB

Want to stay up to date with the project updates ? Our upcoming newsletter is the easiest way! 📰 Every edition will bring you: ✅ Latest project updates ✅ Exclusive interviews with our researchers ✅ Insights into the latest advances in tackling AMR 👉 Sign up now: https://bit.ly/4qDXxMj

In the EU/EEA, drug-resistant infections costs nearly EUR 11.7B per year. This is not just statistics but a call to act. Latest study under PrIMAVeRa shows just how big the burden is, both for health and for cost. 👉 Read the complete paper at: https://bit.ly/46VoQsf

One of the major reason for unsuccessful outcomes are the adverse events (AEs) from TB medications, which can disrupt treatment and reduce success rates. Dr. Simon Tiberi shared practical advice for healthcare teams to prevent treatment interruptions. Learn more: https://bit.ly/4qqxfgu

In our latest study, under UNITE4TB we explore how biomarkers are closing the gap, particularly in challenging cases such as low bacterial load, inability to produce sputum or smear-negative TB. 👉 Read full paper at: https://bit.ly/4ohCFZn

Webinar registration is now open! Join COMBINE, ERA4TB & GNANOW on October 21, Tuesday from 15:00–16:30 CEST for insights on Hollow Fiber Assays in antimicrobial drug development with three experts, Prof. Das, S. Ramon-Garcia & Prof. MacGowan. 👉 Register now: https://bit.ly/3VN3Sa5

Our latest research under @era4tb.bsky.social, highlights that small adjustments in the hollow fiber assays better reflects how TB drugs really perform. Learn more through a webinar on 21 October 2025. 👉 Research paper: https://bit.ly/4q7jIKE 👉 Webinar registration: https://bit.ly/3VN3Sa5

The COMBINE consortium met in Toulouse for its sixth annual meeting and focus is now on making our AMR Accelerator impact last. How do we plan to do that? By keeping datasets FAIR, preserving consortium expertise and embedding results in European & global research infrastructures.

In our latest study under RespiriNTM, zebra fish helped our researchers model nontuberculous mycobacterial infection. Why? Their immune system mirrors humans, letting us study infections effectively and ethically. 👉 Read more at: https://bit.ly/4pS8HwB 👉 Open manuscript: https://bit.ly/3KzNEi8

We are bringing you our latest webinar on Hollow Fibre Assays in antimicrobial drug development, featuring three leading experts. 👉 𝗟𝗲𝗮𝗿𝗻 𝗮𝗯𝗼𝘂𝘁: Building effective hollow fibre systems Case studies Applications in 𝘪𝘯-𝘷𝘪𝘵𝘳𝘰 PK/PD models 👉 Register now: https://bit.ly/3VN3Sa5

Medicines need a reliable teammate to work effectively against resistant bacteria. And Alpibectir is that teammate boosting ethionamide (Eto) to fight resistant bacteria. 👉 Read the complete paper to see the impact of Alpibectir in a first-in-human TRIC-TB study: https://bit.ly/48c5odi

ERA4TB Webinar 📣 How can health systems respond to #AMR through innovation & evidence-based policy? 🌍✨ 🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST 🎙️ Speakers from NICE & WHO 👉 Register: tinyurl.com/ERA4TB @amr-accelerator.bsky.social @amr-accelerator.bsky.social @tballiance.bsky.social

Our researchers found a missing link in applying ML to AMR: lack of clinical and preclinical data. We highlighted the key milestones from data collection to ML models in building the first and public FAIR MIC dataset & AntiMicrobial-KG. Listen to webinar to learn more: bit.ly/472Q8y4

In our latest study, under UNITE4TB consortium, researchers describe how AI could become a powerful ally against TB at the same time highlight challenges that come with this new tech. 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/3Is4E9m

ERA4TB Webinar 📣 How can health systems respond to #AMR through innovation & evidence-based policy? 🌍 Join our ERA4TB webinar 🗓️ 8 Oct 2025 | 1–2pm UK | 2–3pm CEST 🎙️ Speakers from @NICEComms & @WHO 👉 Register: tinyurl.com/ERA4TB @amr-accelerator.bsky.social @who.int @nicecomms.bsky.social

Collaboration in AMR R&D is multisectoral, but not every question moves a project forward. Early scientific advice from EMA is key to understanding what to ask (and not to). 🎥 Watch the complete webinar at: https://bit.ly/4mpXPTx

ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative devoted to accelerate the development of new treatment regimens for #tuberculosis.

Across the EU/EEA, resistant infections add over 9.5M extra hospital days annually. In a study conducted under PrIMAVeRa, our researchers used Bayesian analysis to show each resistant infection adds ~1–2 days, with variable extra costs. 👉 Read more: https://bit.ly/468S1co

Of all the buzzwords this year, none spread faster than "superbugs"! Used in the titles or main public messaging by over half a dozen of major news stories & campaigns (Mar–Sep 2025). Catchy, but does it oversimplify AMR or mislead the public? Share your thoughts on main drawback of this framing.

@era4tb.bsky.social researchers found compounds that block TB’s ESX-1 system (used to damage immune cells) while also improving effectiveness of ethionamide. A dual-action step against drug-resistant TB. 👉 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: bit.ly/3VJJJBw

Why understanding the right dose matters in anti-TB treatment? We broke it down 👇 for you from the start to finish. 👉 Join the UNITE4TB & ERS webinar to learn more on methods that are being used to understand optimal dosing in depth 🔗 https://bit.ly/45QUyYB

“Supercontactors” are the hubs of hospital networks. Controlling their interactions, can help dramatically slow down the spread. Our latest PrIMAVeRa study showcases that targeting them reduced MRSA cases by about 20%. 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁: https://bit.ly/468hBgo

In AMR research, success rarely comes easy. From LpxH inhibitors under Uppsala University to PhagoMed’s pivot (now BioNTech) and Disperazol’s 15-year journey, each story shows how barriers can be turned into pathways for progress. 👉 Hear their lessons and takeaways here: https://bit.ly/47n6d2v

TB bacteria inhabits the air we breathe, exposing most people unknowingly. Yet only 5–10% develop active disease. Research under RespiriNTM and RespiriTB tested amiodarone, to boost immunity by enhancing autophagy against TB. 👉 Read: https://bit.ly/47QD53J

Regulators are not just “approvers,” in AMR R&D they guide the path. The WHO 2025 AMR plan stresses how early advice, adaptive pathways & collaboration can speed safe, effective solutions. Lets us know in comments 👇, do you know what support regulators give developers?

Is monitoring aggregate AMR data enough, or does it hide the gaps? Resistance varies across Europe, and overall prevalence masks the highest-burden regions. The PrIMAVeRa study maps pathogen-specific morbidity and mortality. 👉 Read more: https://bit.ly/3UCvWwk

In 2020, 1,800 immuno-oncology drugs were in development, and only 41 new antimicrobials made trials. Meanwhile, 10.8M people fell ill with TB in 2023. Why such a huge gap? We broke it down into clinical & commercial barriers in TB drug development. Learn more at: https://youtu.be/n6NxPFxHOys

𝗜𝘀 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝗧𝗕 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲? Yes it can be, if patients can continue. 𝗧𝗵𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲? Complex dosing regimens reduce adherence. A UNITE4TB study, models 𝗼𝗻𝗰𝗲-𝗱𝗮𝗶𝗹𝘆 regimens for bedaquiline and delamanid. 👉Read here: https://bit.ly/45estKn

TB care starts in communities, where CSOs help guide and support care, adherence & recovery. True progress needs equal partnerships, yet the sustained funding lags. Join UNITE4TB & ERS panel on meaningful TB community engagement: bit.ly/412Cyrf

𝗛𝗼𝘄 𝘁𝗼 𝘁𝗿𝗮𝗰𝗲 𝗧𝗕 𝗱𝗿𝘂𝗴 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘀𝗺 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗿𝗮𝗱𝗶𝗼𝘁𝗿𝗮𝗰𝗲𝗿𝘀? With more safer and faster approach? Researchers under TRIC-TB consortium used ¹⁹F-NMR, ¹H-NMR & HR-MS to profile alpibectir. 👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿 𝗮𝘁 https://bit.ly/4muyHLJ

Everyone in the antimicrobial resistance ecosystem stands to gain clearer direction, better tools and stronger collaboration with this WHO roadmap (2024–2030). AMR is not just scientific or clinical problem, but a systemic challenge needing multisectoral solutions. 🔗 https://bit.ly/4opZATc

TB survives by fueling its metabolism through a tricky enzyme, cytochrome bc1:aa3. So how do we starve it? Inhibiting isn’t enough, we need to know exactly how it’s blocked. Our new study under Respiri TB, reveals this in detail. 👉 Swipe to learn more 🔗 Full paper: https://bit.ly/4oeme0A

Last week, we got together to focus on a key part of TB research: advancing animal models. Six ERA4TB experts discussed how ethical animal models can drive better treatments for drug-resistant TB and speed up testing of new therapies. While the webinar was internal, the impact is global.

The honest reality check on AMR transmission models every researcher needs. Clarity on what works, what is missing and how to build trust. 👉 Swipe to learn the insights 👉 Read more: bit.ly/46UMqXO #AMR #TB #antimicrobialresistance #research